News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
483,739 Results
Type
Article (8044)
Company Profile (140)
Press Release (475651)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166764)
Career Advice (304)
Deals (25739)
Drug Delivery (7)
Drug Development (52881)
Employer Resources (14)
FDA (9760)
Job Trends (8573)
News (238224)
Policy (17898)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (21)
ADA (18)
Adcomms (1)
Allergies (94)
Alliances (33171)
ALS (103)
Alzheimer's disease (972)
Antibody-drug conjugate (ADC) (258)
Approvals (10356)
Artificial intelligence (315)
ASCO (159)
Autoimmune disease (204)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
BIOSECURE Act (1)
Biosimilars (107)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (135)
Brain cancer (28)
Breast cancer (503)
Cancer (3599)
Cardiovascular disease (215)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (473)
Cervical cancer (34)
Clinical research (47804)
Collaboration (1223)
Commercialization (2)
Compensation (1417)
Complete response letters (34)
COVID-19 (755)
CRISPR (63)
C-suite (725)
Cystic fibrosis (84)
Data (5565)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (337)
Diagnostics (4168)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (151)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (161)
Earnings (73250)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87544)
Executive appointments (690)
FDA (12333)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (900)
Gene editing (125)
Generative AI (9)
Gene therapy (312)
GLP-1 (287)
Government (949)
Grass and pollen (2)
Guidances (280)
Healthcare (9324)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (63)
Immunology and inflammation (98)
Immuno-oncology (55)
Indications (154)
Infectious disease (941)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (83)
Intellectual property (249)
Interviews (42)
IPO (12382)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (3)
Liver cancer (44)
Longevity (15)
Lung cancer (500)
Lymphoma (247)
Machine learning (27)
Management (3)
Manufacturing (520)
Marketing (7)
MASH (117)
Medical device (8647)
Medtech (8780)
Mergers & acquisitions (14369)
Metabolic disorders (697)
mRNA (51)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (217)
Neuropsychiatric disorders (38)
Neuroscience (1805)
NextGen: Class of 2026 (3153)
Non-profit (846)
Obesity (221)
Opinion (10)
Ovarian cancer (157)
Pain (170)
Pancreatic cancer (192)
Parkinson's disease (198)
Partnered (11)
Patents (462)
Patient recruitment (492)
Peanut (31)
People (41201)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15449)
Phase 2 (21346)
Phase 3 (14376)
Pipeline (6831)
Policy (18)
Postmarket research (1572)
Preclinical (6529)
Press Release (34)
Prostate cancer (188)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (563)
Real estate (3024)
Recruiting (6)
Regulatory (14754)
Reports (16)
Research institute (580)
Resumes & cover letters (46)
Rett syndrome (40)
RNA editing (5)
RSV (47)
Schizophrenia (99)
Series A (151)
Series B (119)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (87)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (316)
Venture capital (17)
Weight loss (73)
Women's health (76)
Date
Today (105)
Last 7 days (407)
Last 30 days (1326)
Last 365 days (19159)
2026 (11319)
2025 (19251)
2024 (22988)
2023 (26540)
2022 (34590)
2021 (37171)
2020 (33488)
2019 (23277)
2018 (17498)
2017 (18766)
2016 (17921)
2015 (24268)
2014 (21686)
2013 (18135)
2012 (20224)
2011 (20444)
2010 (20334)
Location
Africa (227)
Alabama (72)
Alaska (2)
Arizona (297)
Arkansas (11)
Asia (17872)
Australia (2093)
California (11669)
Canada (3072)
China (507)
Colorado (470)
Connecticut (399)
Delaware (205)
Europe (24609)
Florida (1745)
Georgia (368)
Hawaii (3)
Idaho (46)
Illinois (687)
India (45)
Indiana (311)
Iowa (14)
Japan (393)
Kansas (99)
Kentucky (30)
Louisiana (26)
Maine (25)
Maryland (1167)
Massachusetts (7697)
Michigan (302)
Minnesota (551)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (112)
New Hampshire (60)
New Jersey (2571)
New Mexico (12)
New York (2765)
North Carolina (1245)
North Dakota (4)
Northern California (5824)
Ohio (271)
Oklahoma (14)
Oregon (16)
Pennsylvania (2216)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (75)
South Dakota (1)
Southern California (4843)
Tennessee (115)
Texas (1886)
United States (37996)
Utah (352)
Vermont (1)
Virginia (151)
Washington D.C. (38)
Washington State (906)
West Virginia (1)
Wisconsin (73)
483,739 Results for "nitto denko avecia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manufactured supply will support upcoming clinical trial in next development phase
June 24, 2026
·
5 min read
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc.
March 31, 2021
·
3 min read
Deals
Nitto Acquires Bend Labs, Inc. in the United States
Nitto Denko Corporation (headquarter: Osaka, Japan, President: Hideo Takasaki, hereafter Nitto) (TOKYO:6988) and Bend Labs, Inc. (US, Co-CEO: Jared Jonas, Colton Ottley, hereafter “Bend”) have agreed on Nitto’s acquisition of Bend.
June 1, 2022
·
2 min read
Business
New President Appointed for Nitto Avecia Inc.
Nitto Denko Avecia Inc. announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.
August 3, 2018
·
2 min read
Business
n-Lorem Foundation Announces Partnership with Nitto Avecia to Strengthen Development of Personalized Medicines for Patients with Ultra-Rare Diseases
n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients with ultra-rare diseases, today announced a new partnership with Nitto Avecia, the world’s largest oligonucleotide therapeutics manufacturer.
June 16, 2021
·
4 min read
Genetown
Nitto Denko Avecia Inc. Announces Multiple Oligonucleotide Expansions
November 14, 2016
·
3 min read
Deals
Nitto Denko Avecia Inc. Acquires The Businesses Of Irvine Pharmaceutical Services, Inc. & Avrio Biopharmaceuticals
October 12, 2016
·
2 min read
Business
Nitto Denko Announces Opening Of Manufacturing Expansion
July 13, 2017
·
2 min read
Business
Nitto Avecia Pharma Services Appoints Raymond Kaczmarek as President
Mr. Kaczmarek joins the organization with nearly 20 years of extensive experience in operations management within the pharmaceutical and biopharmaceutical industries.
January 15, 2018
·
2 min read
Genetown
Nitto Avecia Completes Multiple Successful Oligonucleotide Manufacturing Synthesis Runs at 1.6 Mol Scale
This exciting news comes only months after bringing into operation Avecia’s new API manufacturing synthesis capabilities.
November 7, 2017
·
1 min read
1 of 48,374
Next
